Survival following upfront chemotherapy for treatment-naïve metastatic prostate cancer: a real-world retrospective cohort study

Background Upfront chemotherapy prolongs overall survival for men with metastatic, hormone-sensitive prostate cancer (mHSPC) based on data from clinical trials. We sought to assess the association between upfront chemotherapy and overall survival in men with mHSPC in a real-world cohort. Methods We...

Full description

Saved in:
Bibliographic Details
Published in:Prostate cancer and prostatic diseases 2021-03, Vol.24 (1), p.261-267
Main Authors: Weiner, Adam B., Ko, Oliver S., Li, Eric V., Vo, Amanda X., Desai, Anuj S., Breen, Kieran J., Nadler, Robert B., Morgans, Alicia K.
Format: Article
Language:English
Subjects:
692/699/67/1059
692/699/67/589/466
Analysis
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Chemotherapy
Clinical trials
Cohort analysis
Comorbidity
Confidence intervals
Diagnosis
Metastases
Metastasis
Oncology, Experimental
Prostate cancer
Race
Regression analysis
Statistical analysis
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Upfront chemotherapy prolongs overall survival for men with metastatic, hormone-sensitive prostate cancer (mHSPC) based on data from clinical trials. We sought to assess the association between upfront chemotherapy and overall survival in men with mHSPC in a real-world cohort. Methods We performed a retrospective cohort study of men with de novo, treatment-naïve metastatic prostate cancer from a large, national cancer database in the United States (2014–2015). Men in the upfront chemotherapy group received chemotherapy within 4 months of diagnosis ( n  = 1033, 28%) versus no chemotherapy or chemotherapy later than 12 months after diagnosis (controls; n  = 2704, 72%). Overall survival was assessed using Kaplan–Meier estimates and compared using multivariable Cox regression analysis. Results After a median follow-up of 23 months, median overall survival was 35.7 months in the upfront chemotherapy group and 32.5 months for controls (log-rank p  
ISSN:1365-7852
1476-5608
DOI:10.1038/s41391-020-00278-0